Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
Abstract Background This research aimed to assess the efficacy and safety of combining sintilimab with bevacizumab, oxaliplatin, and capecitabine as a primary therapy for patients with RAS-mutated, microsatellite stable (MSS), and metastatic colorectal cancer (mCRC). Methods In this prospective, ope...
Salvato in:
| Autori principali: | , , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2025-03-01
|
| Serie: | BMC Cancer |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1186/s12885-025-13794-w |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|